DNB Related Funding Opportunities

Genetics, Epigenetics, and Developmental Neuroscience Branch (GEDN)

Program Announcements

  • PAR-25-154 - HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)
  • PAR-24-267 - Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed)
  • PAR-24-269 - NIDA Animal Genomics Program (U01 – Clinical Trial Not Allowed)
  • PAR-23-295 – Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional)
  • PAR-23-294 – Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)
  • PAR-23-293 – Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)
  • PAR-23-076 – NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional)
  • PAR-23-064 – NIDA Program Project Grant Applications (P01 Clinical Trial Optional)
  • PAR-23-049 – NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional)
  • PAR-23-041 – Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed)
  • PAR-23-021 – Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)
  • PAR-21-244 – NIDA Animal Genomics Program (U01 – Clinical Trial Not Allowed)
  • PAR-21-208 – Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional) 

Requests for Application

  • RFA-MH-26-110 - Role of T-Cells in HIV CNS Reservoir Seeding, Persistence, and Neuropathogenesis (R01 Clinical Trial Not Allowed)
  • RFA-MH-26-111 - Role of T-Cells in HIV CNS Reservoir Seeding, Persistence, and Neuropathogenesis (R21 Clinical Trial Not Allowed)
  • RFA-DA-26-009 -  Mitochondrial-associated Mechanisms of Neuropathological and Immunodeficient Aging in the Context of HIV and SUD (R01 Clinical Trials Not Allowed)
  • RFA-DA-26-010 -  Mitochondrial-associated Mechanisms of Neuropathological and Immunodeficient Aging in the Context of HIV and SUD (R21 Clinical Trials Not Allowed)
  • RFA-DA-25-073 -  Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed)
  • RFA-DA-26-001 - Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Functional Validation (R01 Clinical Trial Not Allowed)
  • RFA-DA-25-024 - High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
  • RFA-DA-26-002 - Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Functional Validation (R21 Clinical Trial Not Allowed)
  • RFA-DA-25-060 – High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
  • RFA-DA-25-023 – Integrated Functional Mapping and Molecular Profiling of Cell Ensembles Encoding the Effects of Addictive Substances in Rodents (R01 Clinical Trial Not Allowed)
  • RFA-DA-25-011 – Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R01 Clinical Trial Not Allowed)
  • RFA-DA-24-001 – Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed)

Notices of Special Interest (NOSI)

  • NOT-DA-25-030 – Notice of Special Interest (NOSI): Exploring the Effects of Endocannabinoids and Exogenous Cannabinoids on Brain Development
  • NOT-DA-23-004 – Notices of Special Interest (NOSI): High Priority Areas in Genetics, Epigenetics, and Developmental Neuroscience Branch in the Division of Neuroscience and Behavior
  • NOT-DA-21-020 – Notice of Special Interest (NOSI): Evaluation of sex differences on HIV-associated comorbidities in the context of stimulant use

Notices

  • NOT-DA-24-060 - Notice of Change to Eligibility Information for PAR-24-297, "Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Optional)"
  • NOT-DA-23-041 – Notice of Change to Application Due Date for RFA-DA-22-040, High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
  • NOT-DA-23-037 – Notice of Change to PAR-23-021, Avenir Award Program for Genetic or Epigenetic of Substance Use Disorders (DP1 Clinical Trial Optional)
  • NOT-DA-22-081 – Notice of Intent to Publish a Funding Opportunity Announcement for NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional)

Chemistry and Pharmacology Branch (CP)

Program Announcements

  • PAR-25-110 - Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)
  • PAR-25-111 - Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)
  • PAR-25-114 -  CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational Exploratory/Developmental Research Projects (R21 Clinical Trial Not Allowed)
  • PAR-24-297 - Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Optional)
  • PAR-24-197 - HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)
  • PAR-23-139 – CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational Exploratory/Developmental Research Projects (R21 Clinical Trial Not Allowed)
  • PAR-23-131 – Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)
  • PAR-23-130 – Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)
  • PAR-22-209 – CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early-Stage Development (UG3/UH3 Clinical Trial Not Allowed)
  • PAR-22-032 – Drug Discovery for Nervous System Disorders (R21 Clinical Trials Not Allowed) 
  • PAR-22-031 – Drug Discovery for Nervous System Disorders (R01 Clinical Trials Not Allowed)
  • PAR-21-029 – Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed) 
  • PAR-21-028 – Discovery of Cell-based Chemical Probes for Novel Brain Targets (R21 Clinical Trial Not Allowed) 

Request for Applications

  • RFA-DA-26-034 - Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)
  • RFA-DA-26-007 - Advancing Research on Molecular Targets and Mechanisms that Influence the Interplay Between Sex Hormones, HIV, and Addictive Substances (R01 Clinical Trials Not Allowed)
  • RFA-DA-26-008 - Advancing Research on Molecular Targets and Mechanisms that Influence the Interplay Between Sex Hormones, HIV, and Addictive Substances (R21 Clinical Trials Not Allowed)
  • RFA-DA-25-005 – Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Trial Not Allowed)
  • RFA-DA-24-007 – Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1- Clinical Trial Not Allowed)
  • RFA-DA-23-056 – Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)

Notices of Special Interest (NOSI)

  • NOT-DA-25-032 - Notice of Special Interest (NOSI): Discovery and Development of Natural Products to Treat Substance Use Disorders (SUDs)
  • NOT-AI-24-022 – Notice of Special Interest (NOSI): Chemical Countermeasures Research Program (CCRP) Administrative Supplements to Promote the Development of Pediatric Research Models of Chemical Injury and Medical Countermeasures Discovery
  • NOT-DA-25-027 – Notice of Special Interest (NOSI): Development and Application of Novel Chemical Approaches to Discover Therapeutic Targets for Substance Use Disorders
  • NOT-DA-24-012 – Notice of Special Interest (NOSI): Xylazine: Understanding Its Use and the Consequences
  • NOT-DA-24-005 – Notice of Special Interest (NOSI): Chemoproteomic Approaches for Discovery of Targets and Therapeutics to Treat Substance Use Disorders
  • NOT-DA-24-004 – Notice of Special Interest (NOSI) Targeting Epigenetic Regulators for Treating Addiction and Substance Use Disorders
  • NOT-DA-23-002 – Notice of Special Interest (NOSI): Research in the Chemistry and Pharmacology of Addictive Drugs 
  • NOT-DA-21-033 – Notice of Special Interest (NOSI): Basic Research on Fentanyl and Synthetic Fentanyl Analogs: Signaling, Neurobiology, and Pharmacology 
  • NOT-DA-21-028 – Notice of Special Interest (NOSI): Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects 

Behavioral and Cognitive Neuroscience Branch (BCN)

Program Announcements

  • PAR-23-158 – Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans (BESH) Required)
    PAR-23-157 – Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
  • PAR-21-352 – Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Clinical Trial Required) 
  • PAR-21-350 – Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Clinical Trials Not Allowed) 
  • PAR-21-349 – Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Basic Experimental Studies with Humans Required) 
  • PAR-21-309 – Imaging – Science Track Award for Research Transition (I/START) (R03- Basic Experimental Studies with Humans Required) 
  • PAR-21-310 – Imaging – Science Track Award for Research Transition (I/START) (R03- Clinical Trial Optional)

Requests for Application

  • RFA-OD-25-001 - High-Priority Research in Tobacco Regulatory Science (R01 Clinical Trial Optional)
  • RFA-DA-24-040 - BRAIN Initiative: Brain-Behavior Quantification and Synchronization – Transformative and Integrative Models of Behavior at the Organismal Level (U01 Clinical Trial Optional)
  • RFA-DA-24-041 - BRAIN Initiative: Brain-Behavior Quantification and Synchronization – Transformative and Integrative Models of Behavior at the Organismal Level (U01 Clinical Trials Not Allowed)
  • RFA-DA-25-039 - Education Activities for Responsible Analyses of Complex, Large-Scale Data (R25- Clinical Trial Not Allowed)
  • RFA-DA-24-042 – BRAIN Initiative: Brain-Behavior Quantification and Synchronization – Transformative and Integrative Models of Behavior at the Organismal Level (R34 Clinical Trial Optional)
  • RFA-DA-24-034 – Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Basic Experimental Studies with Humans Required)
  • RFA-DA-24-033 – Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Clinical Trial Optional)
  • RFA-DA-24-032 – Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Basic Experimental Studies with Humans Required)
  • RFA-DA-24-031 – Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Clinical Trial Optional)
  • RFA-EY-23-001 – BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed)
  • RFA-OD-23-017 – Tobacco Regulatory Science (R01 Clinical Trial Optional)
  • RFA-OD-22-026 – Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Required)
  • RFA-OD-22-025 – Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Not Allowed)
  • RFA-OD-22-024 – Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Required)
  • RFA-OD-22-023 – Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Not Allowed)
  • RFA-DA-23-029 – NIDA REI: Research at Minority Serving Institutions on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional)
  • RFA-DA-23-028 – NIDA REI: Research on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional)

Notices of Special Interest (NOSI)

  • NOT-DA-21-030 – Notice of Special Interest (NOSI): Advancing HIV/AIDS Research through Computational Neuroscience 
  • NOT-DA-21-012 - Notice of Special Interest (NOSI): Women and Sex/Gender Differences in Drug and Alcohol Abuse/Dependence 
  • NOT-AT-21-002 – Notice of Special Interest (NOSI): Promoting Research on Interoception and Its Impact on Health and Disease
  • NOT-DA-21-003 - Notice of Special Interest (NOSI): Leveraging Longitudinal Studies in Animal Models to Identify Neural Mechanisms of Vulnerability and Resilience to Substance Use Disorder 

Notices

  • NOT-DA-26-001 -  Notice of Special Interest (NOSI): Advancing Research on SUD with brain-based computational models
  • NOT-NS-24-080 - Request for Information (RFI): BRAIN Initiative: Opportunities and Challenges for Coordinated Neural Stimulating and Recording Efforts to Advance Understanding of Human Neuroscience and Behavior
  • NOT-DA-24-021 – Notice to Extend  Application Due Dates for PAR-21-309 and PAR-21-310, "Imaging - Science Track Award for Research Transition (I/START)"
  • NOT-OD-22-084 – Notice of Intent to Publish the Reissuance of RFA-OD-20-010, Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 – Independent Clinical Trial Required) 
  • NOT-OD-22-083 – Notice of Intent to Publish the Reissuance of RFA-OD-20-009, Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 – Independent Clinical Trial Not Allowed) 
  • NOT-OD-22-082 - Notice of Intent to Publish the Reissuance of RFA-OD-20-011, Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 – Independent Clinical Trial Required) 
  • NOT-OD-22-081 – Notice of Intent to Publish the Reissuance of RFA-OD-20-008, Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 – Independent Clinical Trial Not Allowed) 

Integrative Neuroscience Branch

Program Announcements

  • PAR-25-204 - NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed)
  • PAS-21-270 – AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional) 
  • PAR-21-320 – NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed) 

Request for Applications

  • RFA-DA-25-068 - Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed)
  • RFA-DA-25-069 - Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)
  • RFA-DA-25-073 -  Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed)
  • RFA-DA-25-063 - Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed)
  • RFA-DA-25-005 – Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Trial Not Allowed)
  • RFA-DA-25-023 – Integrated Functional Mapping and Molecular Profiling of Cell Ensembles Encoding the Effects of Addictive Substances in Rodents (R01 Clinical Trial Not Allowed)
  • RFA-DA-25-010 – Interplay of Autophagy Regulated Cell Death and HIV Pathogenesis in Substance Use Disorders (R21 Clinical Trial Not Allowed)
  • RFA-DA-25-009 – Interplay of Autophagy Regulated Cell Death and HIV Pathogenesis in Substance Use Disorders (R01 Clinical Trial Not Allowed)
  • RFA-DA-25-013 – Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed)
  • RFA-DA-25-012 – Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)
  • RFA-DA-25-011 – Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R01 Clinical Trial Not Allowed)
  • RFA-NS-24-021 – HEAL Initiative: Understanding Individual Differences in Human Pain Conditions (R01 - Clinical Trial Optional)
  • RFA-DA-25-014 – Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed)
  • RFA-OD-22-014 – Specialized Centers of Research Excellence (SCORE) on Sex Differences (U54 Clinical Trial Optional)

Notices of Special Interest (NOSI)

  • NOT-DA-25-028 – Notice of Special Interest (NOSI): Myelin plasticity in sculping addiction neurocircuitry
  • NOT-MH-24-105 – Notice of Special Interest (NOSI): Fundamental Mechanisms and Functions of Co-transmission in the Brain
  • NOT-DA-24-007 – Notice of Special Interest (NOSI): Assembling the Addiction Organelle Interactome
  • NOT-DA-24-006 – Notice of Special Interest (NOSI): Leveraging glial cells to treat addiction
  • NOT-DA-22-048 – Notice of Special Interest (NOSI): Targeting the Endocannabinoid System for Brain Health and Acute and Chronic Diseases
  • NOT-DA-22-058 – Notices of Special Interest (NOSI): High Priority Areas in Integrative Neuroscience Branch in the Division of Neuroscience and Behavior 
  • NOT-DA-22-047 – Notice of Special Interest (NOSI): Mechanistic studies on the impact of substance use in sex and gender differences in HIV-associated neurocognitive disorders 
  • NOT-DA-21-030 – Notice of Special Interest (NOSI): Advancing HIV/AIDS Research through Computational Neuroscience 
  • NOT-DA-21-006 - Notice of Special Interest (NOSI): Leveraging transformative connectome resources in model organisms to elucidate the neurobiology of substance use disorders 
  • NOT-DA-21-014 - Notice of Special Interest (NOSI): Identification of Biomarkers of HIV Pathogenesis and Substance Use Disorder Comorbidity 
  • NOT-DA-21-001 – Notice of Special Interest (NOSI): Deciphering the Mosaic of Glia in the Addicted Brain

Notices

  • NOT-DA-24-022 – Notice of Change to Application Due Date for PAS-21-270, "AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional)"
  • NOT-DA-22-070 – Notice of Intent to Publish a Funding Opportunity Announcement for Targeting Inflammasomes in Substance Abuse and HIV (R01 Clinical Trial Not Allowed) 
  • NOT-DA-22-055 – Notice of Change to section for PAR-21-320, NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed)

Office of the Director

Program Announcements 

  • PAS-24-242 - D-START: Data Science Track Award for Research Transition (D/START) (R03-Clinical Trial Optional)
  • PAR-23-194 – Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed)
  • PAR-23-076 – NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional)
  • PAR-23-064 – NIDA Program Project Grant Applications (P01 Clinical Trial Optional)
  • PAR-23-049 – NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional)
  • PAR-21-320 – NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed) 

Requests for Applications

  • RFA-OD-24-010 - Building Sustainable Software Tools for Open Science (R03 Clinical Trial Not Allowed)
  • RFA-OD-24-011 - NIH Research Software Engineer (RSE) Award (R50 Clinical Trials Not Allowed)
  • RFA-DA-24-041 - BRAIN Initiative: Brain-Behavior Quantification and Synchronization – Transformative and Integrative Models of Behavior at the Organismal Level (U01 Clinical Trials Not Allowed)
  • RFA-DA-24-040 - BRAIN Initiative: Brain-Behavior Quantification and Synchronization – Transformative and Integrative Models of Behavior at the Organismal Level (U01 Clinical Trial Optional)
  • RFA-OD-24-013 – Building Interdisciplinary Research Careers in Women's Health (BIRCWH) (K12 Clinical Trial Optional)
  • RFA-DA-23-039 – BRAIN Initiative: Theories, Models and Methods for Analysis of Complex Data from the Brain (R01 Clinical Trial Not Allowed)

Notices of Special Interest (NOSI)

  • NOT-DA-24-029 - Notice of Special Interest (NOSI): High-Priority Interest to Enhance Data Science Research Training in Addiction Research
  • NOT-CA-24-031 - Notice of Special Interest (NOSI): Validation of Digital Health and Artificial Intelligence/Machine Learning Tools for Improved Assessment in Biomedical and Behavioral Research
  • NOT-OD-24-026 – Notice of Special Interest (NOSI): Advance Data Science Approaches Through Secondary Data Analysis to Reveal Scientific Insights of COVID-19 Testing Technologies (R21)
  • NOT-NS-23-092 – Notice of Special Interest: Administrative Supplements for the U.S.-Japan Brain Research Cooperative Program (BRCP) - U.S. Entity (Admin Supp)
  • NOT-OD-23-040 – Notice of Special Interest (NOSI): Advance Data Science Approaches Through Secondary Data Analysis to Reveal Scientific Insights of COVID-19 Testing Technologies (R21)
  • NOT-MH-21-175 – Notice of Special Interest (NOSI) regarding the use of Human Connectome Data for Secondary Analysis 
  • NOT-AI-21-054 – Notice of Special Interest (NOSI): Harnessing Big Data to Halt HIV 
  • NOT-DA-21-030 – Notice of Special Interest (NOSI): Advancing HIV/AIDS Research through Computational Neuroscience 
  • NOT-DA-21-013 – Notice of Special Interest (NOSI): High-Priority Interest to Enhance Data Science Research Training in Addiction Research 
  • NOT-DA-21-004 – Notice of Special Interest (NOSI): Advanced Computational Approaches to Elucidate Disease Pathology and Identify Novel Therapeutics for Addiction 
  • NOT-DA-23-006 – Notice of Special Interest (NOSI): Leveraging Data Science to Bring Actionable Insights for Substance Use Prevention and Treatment

Notices

  • NOT-DA-24-038 - Notice of Information: Updates to the Data Repository for the Adolescent Brain Cognitive Development (ABCD) Study and the HEALthy Brain and Child Development (HBCD) Study
  • NOT-DA-24-030 - Notice to  Update PAR-23-194, "Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed)"
  • NOT-DA-24-014 – Notice of NIDA's Participation in RFA-HG-23-002, Broadening Opportunities for Computational Genomics and Data Science Education (UE5 – Clinical Trial Not Allowed)
  • NOT-DA-23-049 – Notice of Change to PAR-23-194, Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed)
  • NOT-DA-23-038 – Notice of Joint NSF/NIDA Initiative to Support Research in the Incorporating Human Behavior into Epidemiological Models Program
  • NOT-OD-23-165 – Notice of NIH Participation in the National Science Foundation Solicitation NSF 23-614: Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science
  • NOT-DA-22-055 – Notice of Change to section for PAR-21-320, NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed)